Preview

Современная ревматология

Расширенный поиск

Роль лабораторных биомаркеров в мониторинге и прогнозировании эффективности терапии ревматических заболеваний генно-инженерными биологическими препаратами

https://doi.org/10.14412/1996-7012-2014-1-5-13

Полный текст:

Аннотация

Значительный прогресс в лечении иммуновоспалительных ревматических заболеваний (РЗ) связан с разработкой нового класса лекарственных средств – генно-инженерных биологических препаратов (ГИБП). В настоящее время в крови, синовиальной жидкости, моче и биоптатах пораженных тканей выявлены молекулярные и клеточные биомаркеры (антитела, показатели острой фазы воспаления, цитокины, хемокины, факторы роста, маркеры активации эндотелия, иммуноглобулины, криоглобулины, субпопуляции Т- и В-лимфоцитов, продукты метаболизма костной и хрящевой ткани, генетические, метаболические маркеры), позволяющие осуществлять иммунологический мониторинг и прогнозирование эффективности терапии РЗ ингибиторами фактора некроза опухоли α (инфликсимаб, адалимумаб, голимумаб, этанерцепт), анти-В-клеточными препаратами (ритуксимаб, белимумаб), антагонистом рецептора интерлейкина 6 (тоцилизумаб), блокатором костимуляции Т-клеток (абатацепт). Наряду с традиционными униплексными методами иммунодиагностики все шире применяется мультиплексный анализ биомаркеров, основанный на генетических, транскриптомных и протеомных технологиях с использованием ДНК- и белковых микрочипов, полимеразной цепной реакции, проточной цитометрии. Поиск и валидация иммунологических предикторов эффективного ответа на терапию ГИБП создает предпосылки для оптимизации и снижения стоимости лечения этими препаратами.

Об авторах

Елена Николаевна Александрова
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия; 115522, Москва, Каширское ш., 34A
Россия


А. А. Новиков
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия; 115522, Москва, Каширское ш., 34A
Россия


Евгений Львович Насонов
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва, Россия; 115522, Москва, Каширское ш., 34A
Россия


Литература

1. <div><p>McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):е297.</p><p>Фоломеева ОМ, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяции России и США. Научно-практическая ревматология. 2008;(4):4–13. [Folomeeva OM, Galushko EA, Erdes SF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Rheumatology Science and Practice. 2008;(4):4–13.]. DOI: http://dx.doi.org/10.14412/1995-4484-2008-529.</p><p>Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. 344 с. [Nasonov EL, editor. Anti-V-kletochnaya terapiya v revmatologii: fokus na rituksimab. Moscow: IMA-PRESS; 2012. 344 p.]</p><p>Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Moscow: IMA-PRESS; 2013. 552 p.]</p><p>Bansard C, Lequerrе T, Daveau M, et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology (Oxford). 2009;48(9):1021–8. DOI: 10.1093/rheumatology/kep112. Epub 2009 May 29.</p><p>Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis. Clinical efficacy and predictors of response. BioDrugs. 2009;23(2):111–24. DOI: 10.2165/00063030-200923020-00004.</p><p>Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? Autoimmun Rev. 2010;9(12):801–3. DOI: 10.1016/j.autrev.2010.07.006. Epub 2010 Jul 23.</p><p>Александрова ЕН, Новиков АА, Соловьев СК и др. В-клетки при аутоиммунных ревматических заболеваниях. В кн.: Анти-В- клеточная терапия в ревматологии: фокус на ритуксимаб. Насонов ЕЛ, редактор. Москва: ИМА- ПРЕСС; 2012. С. 8–45. [Aleksandrova EN, Novikov AA, Solov'ev SK i dr. V-kletki pri autoimmunnykh revmaticheskikh zabolevaniyakh. V kn.: Anti-V- kletochnaya terapiya v revmatologii: focus na rituksimab. Nasonov EL, editor. Moscow: IMA- PRESS; 2012. P. 8–45.]</p><p>Александрова ЕН, Новиков АА, Насонов ЕЛ. Роль лабораторных биомаркеров в оценке эффективности терапии ревматоидного артрита генно-инженерными биологическими препаратами. В кн.: Генно-инженерные биологические препараты в лечении ревматоидного артрита. Насонов ЕЛ, редактор. Москва: ИМАПРЕСС; 2013. С. 101–22. [Aleksandrova EN, Novikov AA, Nasonov EL. Rol' laboratornykh biomarkerov v otsenke effektivnosti terapii revmatoidnogo artrita genno-inzhenernymi biologicheskimi preparatami. V kn.: Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Nasonov EL, editor. Moscow: IMA-PRESS; 2013. P. 101–22.]</p><p>Насонов ЕЛ, Гусева ИА, Александрова ЕН. Проблемы персонифицированной терапии ревматоидного артрита генно-инженерными биологическими препаратами. В кн.: Генно-инженерные биологические препараты в лечении ревматоидного артрита. Насонов ЕЛ, редактор. Москва: ИМА-ПРЕСС; 2013. С. 489–509. [Nasonov EL, Guseva IA, Aleksandrova EN. Problemy personifitsirovannoi terapii revmatoidnogo artrita genno-inzhenernymi biologicheskimi preparatami. V kn.: Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Nasonov EL, editor. Moscow: IMA-PRESS; 2013. P. 489–509.]</p><p>Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(12):1794–803. DOI: http://dx.doi.org/10.1002/acr.21767.</p><p>Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306–11. DOI: http://dx.doi.org/10.1097/BOR.0b013e3283521c4e.</p><p>Menzies D, Pai M, Comstock G. Metaanalysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146(5):340–54. DOI: http://dx.doi.org/10.7326/0003-4819-146-5-200703060-00006.</p><p>Bruns A, Nicaise-Roland P, Hayem G, et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine. 2009;76(3):248–53. DOI: http://dx.doi.org/10.1016/j.jbspin.2008.09.010.</p><p>Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69–74. DOI: http://dx.doi.org/10.1136/ard.2007.084715.</p><p>Sekigawa I, Yanagida M, Iwabuchi K, et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol. 2008;26(2):261–7.</p><p>Dwivedi RC, Dhindsa N, Krokhin OV, et al. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res Ther. 2009;11(2):R32. DOI: http://dx.doi.org/10.1186/ar2637.</p><p>Fabre S, Dupuy AM, Dossat N, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol. 2008;153(2):188–95. DOI: http://dx.doi.org/10.1111/j.1365-2249.2008.03691.x.</p><p>Hueber W, Tomooka BH, Batliwalla F, et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R76. DOI: http://dx.doi.org/10.1186/ar2706.</p><p>Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis. 2008;67(8):1139–44. DOI: http://dx.doi.org/10.1136/ard.2007.080440.</p><p>Morozzi G, Fabbroni M, Bellisai F, et al. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol. 2007;26(8):1335–8. DOI: http://dx.doi.org/10.1007/s10067-006-0520-y. Epub 2007 Feb 7.</p><p>Gonzаlez-Alvaro I, Ortiz AM, Tomero EG, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis. 2007;66(12):1675–8. DOI: http://dx.doi.org/10.1136/ard.2007.071910.</p><p>Visvanathan S, Rahman MU, Keystone E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther. 2010;12(6):R211. DOI: 10.1186/ar3188. Epub 2010 Nov 17.</p><p>Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis. 2012;71(5):674–80. DOI: 10.1136/ard.2010.148890. Epub 2011 Oct 28.</p><p>Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70(2):284–8. DOI: 10.1136/ard.2010.135111. Epub 2010 Nov 10.</p><p>Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8(6):515–9. DOI: 10.1016/j.autrev.2009.01.007. Epub 2009 Jan 30.</p><p>Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122(1):62–74. DOI: http://dx.doi.org/10.1016/j.clim.2006.08.016. Epub 2006 Oct 13.</p><p>Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66(9):1259–62. DOI: http://dx.doi.org/10.1136/ard.2006.067124. Epub 2007 Apr 5.</p><p>Tew GW, Rabbee N, Wolslegel K, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19(2):146–57. DOI: 10.1177/0961203309350752. Epub 2009 Nov 27.</p><p>Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis. 2008;67(12):1724–31. DOI: 10.1136/ard.2007.083162. Epub 2008 Feb 4.</p><p>Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):83. DOI: http://dx.doi.org/10.1186/ar1954. Epub 2006 May 5.</p><p>Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56(4):1263–72. DOI: http://dx.doi.org/10.1002/art.22505.</p><p>Dass S, Rawstron AC, Vital EM, et al. High sensitivity B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2993–9. DOI: 10.1002/art.23902.</p><p>Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide : clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67(3):330–4. DOI: http://dx.doi.org/10.1136/ard.2007.079095. Epub 2007 Sep 7.</p><p>Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826–33. Epub 2008 Apr 1.</p><p>Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cell after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613–20. DOI: http://dx.doi.org/10.1002/art.21617.</p><p>Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.Arthritis Rheum. 2007;56(9):3044–56. DOI: http://dx.doi.org/10.1002/art.22810.</p><p>Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58(6):1566–75. DOI: 10.1002/art.23473.</p><p>Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis. 2009;68(6):1011–6. DOI: 10.1136/ard.2008.092791. Epub 2008 Jul 22.</p><p>Moller B, Aeberli D, Eggli S, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R62. DOI: 10.1186/ar2686. Epub 2009 May 6.</p><p>Sellam J, Abbedd K, Rouanet S, et al. Pre-therapeutic descrease frequency of memory B cell is predictive of response to a first course of rituximab in rheumatoid arthritis patients with inadequate respose or intolerance to anti-TNF: data from the SMART trial. Ann Rheum Dis. 2010;69 Suppl 3:490.</p><p>Blom M, Wenink M, Huijbens R, et al. Altered сirculating сytokine pattern after administration of rituximab is correlated with response to therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58:450.</p><p>Fabre S, Gvisset C, Tatem L, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol. 2008;155(3):395–402. DOI: 10.1111/j.1365-2249.2008.03804.x.</p><p>Thurlings RM, Boumans MJH, Vos K, et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to rituximab treatment in rheumatoid arthritis. Arthritis Rheum. 2009;60 Suppl.:630(1686).</p><p>Vallerskog T, HeimbЯrger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8(6):R167. DOI: http://dx.doi.org/10.1186/ar2076.</p><p>Pers JO, Devauchelle V, Daridon C, et al. BAFF-Modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56(5):1464–77. DOI: http://dx.doi.org/10.1002/art.22603.</p><p>Ferraccioli G, Tolusso B, Pallavicini FB, et al. Biomarkers predictors of good EULAR response to B cell depletion therapy (BCDT) in seropositive rheumatoid arthritis patients. Arthritis Rheum. 2010;62(Suppl 10):1098.</p><p>Moura RA, De La Torre I, Leandro R, et al. BAFF-R expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis (RA) following B cell depletion therapy. Ann Rheum Dis. 2010;69(Suppl 3):379.</p><p>Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to TNF antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post-hocanalysis of a predominantly Hispanic Cohort. Arthritis Rheum. 2010;62(2):392–401. DOI: 10.1002/art.27226.</p><p>Авдеева АС, Александрова ЕН, Панасюк ЕЮ и др. Влияние терапии тоцилизумабом на иммунологические показатели у больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(3):25–32. [Avdeyeva AS, Aleksandrova EN, Panasyuk EY, et al. Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2012;50(3):25–32.]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-705.</p><p>Kawashiri S, Kawakami A, Iwamoto N, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011;21(4):370–4. DOI: 10.1007/s10165-010-0409-0. Epub 2011 Jan 15.</p><p>Yamana J, Iwahashi M, Kim M, et al. T-cell-related cytokines are inhibited in response to tocilizumab in patients with rheumatoid arthritis in contrast with TNF Inhibitor. Arthritis Rheum. 2011;Suppl.63:S18(51).</p><p>Novikov A, Alexandrova E, Panasiuk E, et al. Characteristics of a cytokine profile of peripheral blood following interleukin 6-receptor antagonist Tocilizumab (TCZ) therapy for rheumatoid arthritis (RA). Ann Rheum Dis. 2011;70 (Suppl.3):720.</p><p>Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33–43. DOI: 10.1002/art.25053.</p><p>Roll P, Muhammad K, Schumann M, et al. In vivo effect of the anti interleukin-6 receptor inhibitor tocilizumab on the B-cell compartment. Arthritis Rheum. 2011;63(5):1255–64. DOI: 10.1002/art.30242.</p><p>Huizinga T, Emery W, Westhovens P, et al. Rate of anti-cyclic citrullinated peptide antibody and rheumatoid factor seroconversion in patients with undifferentiated arthritis or early rheumatoid arthritis treated with abatacept. Arthritis Rheum. 2011;63 (Suppl10):2232.</p><p>Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis. 2012;71(11):1815–9. DOI: 10.1136/annrheumdis-2011-201109. Epub 2012 May 21.</p><p>Scarsi M, Ziglioli T, Airy P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010 May;37(5):911–6. DOI: 10.3899/jrheum.091176. Epub 2010 Mar 15.</p><p>Pieper J, Herrath J, Raghavan S, et al. CTLA4-Ig (abatacept) therapy modulates T-cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34. DOI: 10.1186/1471-2172-14-34.</p><p>Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37. DOI: http://dx.doi.org/10.1002/art.34400.</p></div><br />


Для цитирования:


Александрова Е.Н., Новиков А.А., Насонов Е.Л. Роль лабораторных биомаркеров в мониторинге и прогнозировании эффективности терапии ревматических заболеваний генно-инженерными биологическими препаратами. Современная ревматология. 2014;8(1):5-13. https://doi.org/10.14412/1996-7012-2014-1-5-13

For citation:


Aleksandrova E.N., Novikov A.A., Nasonov E.L. Role of laboratory biomarkers in monitoring and prediction of the effectiveness of treatment of rheumatic diseases using genetically engineered drugs. Modern Rheumatology Journal. 2014;8(1):5-13. (In Russ.) https://doi.org/10.14412/1996-7012-2014-1-5-13

Просмотров: 6533


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)